The CD133-high fraction from glioma cells was more resistant to radiotherapy than the CD133-negative fraction, and CD133-high cells activated the molecular event for the DNA damage checkpoint and enhanced DNA repair capacity following radiotherapy (46). The gene discussed is PROM1; the disease is central nervous system cancer.